Description
Lyell Immunopharma is a T-cell reprogramming company. The Company offers T cells to cure patients with solid tumors.
Its technologies are designed to be applied in a target and agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies to improve the properties of T cells to eradicate solid tumors. It builds a multi-modality product pipeline across solid tumor indications with unmet needs. It offers Gen-R and Epi-R technology platforms.
Its Gen-R is its ex vivo genetic reprogramming technology to overcome T cell exhaustion. Its Epi-R is an ex vivo epigenetic reprogramming technology to create a population of T cells with durable stemness.
Epi-R is designed to generate populations of T cells that have the property of durable stemness. The Company is applying its Epi-R technology to develop its product candidate, LYL845. The Company is based in South San Francisco, California and Seattle, and Bothell, Washington.
